Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma

Gynecologic Oncology Research and Practice
Graziela Zibetti Dal MolinFernando Cotait Maluf

Abstract

Ovarian carcinosarcoma is a rare malignancy associated with a high rate of cancer-related mortality even at early stages. Guidelines for systemic treatment have been difficult to establish because the disease is commonly excluded from prospective clinical trials. Ovarian carcinosarcoma is usually managed as high-grade epithelial ovarian cancer despite major histologic differences. Owing to the rarity and poor prognosis of ovarian carcinosarcoma, salvage treatments and their efficacy have been poorly described. A patient heavily treated for ovarian carcinosarcoma showed an objective response to an immune checkpoint inhibitor, pembrolizumab. Pembrolizumab in this patient appeared to provide tumor control in multifocal metastatic sites. Pembrolizumab should be evaluated in prospective trials for the treatment of ovarian carcinosarcoma and further work is needed to identify patients most likely to respond to this type of intervention.

References

May 1, 1953·The British Journal of Radiology·R H MOLE
Mar 23, 2011·Gynecologic Oncology·J Alejandro Rauh-HainMarcela G del Carmen
Jul 12, 2011·Best Practice & Research. Clinical Obstetrics & Gynaecology·Emanuela D'Angelo, Jaime Prat
Dec 14, 2011·Gynecologic Oncology·Marcela G del CarmenJohn O Schorge
May 10, 2012·Journal of the National Cancer Institute·Rachel Ballard-BarbashCatherine M Alfano
Mar 19, 2014·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·UNKNOWN FIGO Committee on Gynecologic Oncology
Sep 6, 2014·Chinese Journal of Cancer·Elad SharonHelen X Chen
Oct 25, 2014·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Dominique Berton-RigaudIsabelle Ray-Coquard
Sep 10, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Junzo HamanishiIkuo Konishi
Apr 10, 2016·Virchows Archiv : an International Journal of Pathology·Laura ArdighieriFabio Facchetti
Jul 23, 2016·International Journal of Molecular Sciences·Gloria MitticaGiorgio Valabrega
Oct 30, 2016·Proceedings of the National Academy of Sciences of the United States of America·Siming ZhaoAlessandro D Santin

❮ Previous
Next ❯

Citations

Jan 2, 2020·Clinical Case Reports·Joshua D BernstockMina Lobbous
Oct 18, 2019·Seminars in Cancer Biology·Holly E Barker, Clare L Scott
Feb 23, 2020·Pathology, Research and Practice·Sean HackingMansoor Nasim
Dec 17, 2020·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Taylor M JenkinsAnne M Mills

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinosarcoma

Carcinosarcoma is a malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. Discover the latest research on carcinosarcoma here.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
Mauro SignorelliNicoletta Colombo
Gynecologic Oncology
J Alejandro Rauh-HainMarcela G Del Carmen
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Chia-Lin HsuYih-Leong Chang
Tennessee Medicine : Journal of the Tennessee Medical Association
Millard Ray LambEleanor Middlemas
© 2022 Meta ULC. All rights reserved